Actively Recruiting
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)
Led by Jonsson Comprehensive Cancer Center · Updated on 2026-02-05
43
Participants Needed
1
Research Sites
268 weeks
Total Duration
On this page
Sponsors
J
Jonsson Comprehensive Cancer Center
Lead Sponsor
V
Varian Medical Systems
Collaborating Sponsor
AI-Summary
What this Trial Is About
This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor control in patients with primary or recurrent, localized or metastatic head and neck cancer (HNC) who are ineligible for or decline standard of care treatment. Researchers want to evaluate if using HyperArc and PULSAR together will deliver higher, possibly more effective doses, resulting in better tumor control with the same or fewer side effects than smaller routine doses. PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment. HyperArc radiation treatment planning technology is a tool that allows for target dose escalation to tumor tissue while maintaining minimal head and neck organs-at-risk doses compared to other radiation treatment planning software. Undergoing PULSAR and HyperArc technology together may be a safe and effective palliative treatment option for patients with HNC.
CONDITIONS
Official Title
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- Diagnosis of primary or recurrent, localized or metastatic head and neck cancer (AJCC 8th Edition stages I-IV)
- Pathologic confirmation for primary diagnosis; clinical or radiographic evidence for recurrent/metastatic diagnosis
- Ineligible for or declines standard definitive treatments, documented in medical records
- Measurable disease in head and/or neck by clinical exam or imaging within 30 days before enrollment
- Maximum tumor or tumor bed diameter under 10 cm
- Negative pregnancy test within 1 week before treatment start for women of childbearing potential
- Agreement to use adequate contraception during study and for 4 weeks after treatment (for women of childbearing potential)
- Patients with tracheostomy and/or feeding tube are eligible
You will not qualify if you...
- Pregnant or breastfeeding
- More than one prior radiation treatment course to the treatment area in lifetime
- One prior radiation course must have ended at least 6 months before enrollment
- Any medical condition or comorbidity that would prevent full compliance with the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California at Los Angeles
Los Angeles, California, United States, 90095
Actively Recruiting
Research Team
M
Mili Santoso
CONTACT
V
Vincent Basehart
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here